We scan new podcasts and send you the top 5 insights daily.
Manali says there is no data for prophylactic tocilizumab with lymphoma CD20 bispecifics, unlike myeloma, so she does not use it. Patients instead receive PJP and HSV prophylaxis and have IgG checked, with IVIG for IgG below 400 or recurrent infections. That prophylaxis package differs from CAR T.
Prophylactically administering tocilizumab before bispecific antibody treatment can slash the incidence of cytokine release syndrome (CRS) from ~75% down to 20%. This simple intervention, analogous to using G-CSF for neutropenia, mitigates side effects and makes outpatient administration a much safer and more feasible option for patients.
While prophylactic tocilizumab is used to mitigate CRS with bispecific antibodies in multiple myeloma, this practice should not be applied to lymphoma patients. Rates of high-grade CRS with CD20-bispecifics in lymphoma are low single digits, making routine prophylaxis unnecessary and exposing patients to a drug they likely don't need.
While prophylactic tocilizumab is standardly adopted to reduce CRS in multiple myeloma patients receiving BCMA-targeted bispecifics, it is unnecessary for CD20-targeted lymphoma bispecific antibodies. Due to differing tumor microenvironments and targets, CD20 bispecifics carry a distinct toxicity profile where routine tocilizumab prophylaxis provides no demonstrable clinical need, reserving the IL-6 inhibitor strictly for grade 2 or higher CRS.
Administering tocilizumab before the first bispecific antibody dose significantly reduces Cytokine Release Syndrome (CRS) risk. This proactive strategy enables safer outpatient treatment, lowering hospital admissions and improving patient access, especially in community settings.
Because bispecific antibody regimens are administered over numerous cycles (8 to 12 cycles or more), normal B cells are continually suppressed and cannot recover. This induces severe, persistent hypogammaglobulinemia. All patients receiving B-cell bispecifics require acyclovir prophylaxis for shingles, PJP prophylaxis if receiving steroids, and regular IVIG replacement therapy to avoid chronic sinus and upper respiratory tract infections.
Giving tocilizumab prophylactically before bispecific antibody administration is a key strategy to mitigate Cytokine Release Syndrome. This practice, supported by NCCN guidelines and generally reimbursed, significantly reduces CRS risk, making it safer and more feasible to deliver these therapies in an outpatient setting.
The IntentiMig trial showed that proactively administering tocilizumab with a bispecific antibody resulted in a zero percent incidence of cytokine release syndrome (CRS). This safety improvement could be pivotal for the broader adoption of bispecifics in community oncology settings, which are less equipped to manage severe side effects.
The tolerability of therapies like bispecific antibodies has significantly improved not from changing the drug, but from evolving supportive care. Implementing low-threshold protocols for interventions like tocilizumab (for CRS) and IVIG (for infections) has made these once-complex treatments much safer and more manageable.
To manage hypogammaglobulinemia from bispecific antibodies, clinicians are adopting a more proactive approach. Following the model from myeloma care, they are initiating IVIG therapy earlier to prevent infections, rather than waiting for recurrent infections to occur as was standard with rituximab.
Giving prophylactic tocilizumab before bispecific antibody administration is a highly effective strategy to mitigate Cytokine Release Syndrome (CRS). This approach can reduce CRS rates from ~70% to 5-14%, making outpatient step-up dosing a much more feasible and safer option for community oncology centers.